Details for Patent: 8,337,890
✉ Email this page to a colleague
Which drugs does patent 8,337,890 protect, and when does it expire?
Patent 8,337,890 protects DYANAVEL XR 10, DYANAVEL XR 15, DYANAVEL XR 20, DYANAVEL XR 5, and NEXICLON XR, and is included in two NDAs.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 8,337,890
| Title: | Modified release formulations containing drug-ion exchange resin complexes |
| Abstract: | A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. |
| Inventor(s): | Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ) |
| Assignee: | Tris Pharma Inc (Monmouth Junction, NJ) |
| Application Number: | 12/722,857 |
|
Patent Claim Types: see list of patent claims | Composition; Process; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 8,337,890
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | DYANAVEL XR 10 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-002 | Nov 4, 2021 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Tris Pharma Inc | DYANAVEL XR 20 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-004 | Nov 4, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-001 | Dec 3, 2009 | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Athena | NEXICLON XR | clonidine | TABLET, EXTENDED RELEASE;ORAL | 022500-002 | Dec 3, 2009 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,337,890
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E536867 | ⤷ Subscribe | |||
| Australia | 2007227569 | ⤷ Subscribe | |||
| Brazil | PI0709606 | ⤷ Subscribe | |||
| Canada | 2645855 | ⤷ Subscribe | |||
| China | 101400343 | ⤷ Subscribe | |||
| China | 102488652 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
